Personalized follow-up using circulating DNA in melanoma patients
Personalized Circulating DNA Follow-up in Melanoma
This study is testing if tracking tumor DNA in the blood can help doctors better monitor and manage treatment for patients with advanced melanoma.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 165 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Institut de Cancérologie de Lorraine Academic / other |
| Drugs / interventions | immunotherapy |
| Locations | 8 sites (Besançon and 7 other locations) |
| Trial ID | NCT04866680 on ClinicalTrials.gov |
What this trial studies
PERCIMEL is an open multicentric study designed to evaluate the effectiveness of molecular analysis of circulating tumor DNA for monitoring melanoma progression. The study focuses on patients with locally advanced, operable melanoma who have undergone treatment with immunotherapy or targeted therapies. By analyzing circulating DNA, the study aims to provide personalized follow-up care that could enhance disease management and patient outcomes.
Who should consider this trial
Good fit: Ideal candidates for this study are patients with locally advanced, operable melanoma who have received immunotherapy or targeted therapies.
Not a fit: Patients with a second cancer or those who are pregnant or breastfeeding may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more tailored and effective monitoring of melanoma, potentially improving patient outcomes.
How similar studies have performed: Other studies have shown promise in using circulating tumor DNA for monitoring various cancers, suggesting potential success for this approach in melanoma.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * locally advanced, operable melanoma * treated by immunotherapy or anti-BRAF and anti-MEK targeted therapies (stage IIIb, IIIc) or exclusive immunotherapy (stage IV) in an adjuvant situation. Exclusion Criteria: * second cancer * woman who is pregnant, likely to be pregnant or breastfeeding
Where this trial is running
Besançon and 7 other locations
- CHU Jean Minjoz — Besançon, France (Recruiting)
- Cgfl — Dijon, France (Recruiting)
- Chu Dijon — Dijon, France (Recruiting)
- Chru Lille — Lille, France (Recruiting)
- Ghr Mulhouse Sud Alsace — Mulhouse, France (Recruiting)
- Institut Godinot — Reims, France (Recruiting)
- Institut de Cancerologie de Lorraine — Vandœuvre-lès-Nancy, France (Recruiting)
- Chru Nancy — Vandœuvre-lès-Nancy, France (Recruiting)
Study contacts
- Study coordinator: MERLIN JEAN-LOUIS, PharmD, PhD
- Email: jl.merlin@nancy.unicancer.fr
- Phone: 33 3 83 65 60 62
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.